Literature DB >> 28706910

Malignant pleural mesothelioma: adjuvant therapy with radiation therapy.

Kenneth E Rosenzweig1.   

Abstract

It is a challenge to treat malignant pleural mesothelioma with radiation therapy (RT). For many years, conventional RT was delivered after extrapleural pneumonectomy (EPP) with acceptable results. However, the benefit of RT has never been definitively proven. Intensity modulated radiation therapy (IMRT) has been used, but some of the early experiences revealed fatal toxicity. As experience has increased, it now appears that RT, particularly with IMRT, is both feasible and effective.

Entities:  

Keywords:  Mesothelioma; intensity modulated radiation therapy (IMRT); radiation pneumonitis; radiotherapy

Year:  2017        PMID： 28706910      PMCID： PMC5497112          DOI： 10.21037/atm.2017.06.25

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


  26 in total

1.  SMART or simply bold?

Authors:  Valerie W Rusch; Andreas Rimner; Prasad S Adusumilli
Journal:  J Thorac Cardiovasc Surg       Date:  2015-10-23       Impact factor: 5.209

2.  Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.

Authors:  Fauzia Shaikh; Marjorie G Zauderer; Donata von Reibnitz; Abraham J Wu; Ellen D Yorke; Amanda Foster; Weiji Shi; Zhigang Zhang; Prasad S Adusumilli; Kenneth E Rosenzweig; Lee M Krug; Valerie W Rusch; Andreas Rimner
Journal:  J Thorac Oncol       Date:  2017-03-21       Impact factor: 15.609

3.  Helical tomotherapy for resected malignant pleural mesothelioma: dosimetric evaluation and toxicity.

Authors:  Philippe Giraud; Alma Sylvestre; Sofia Zefkili; Albert Lisbona; Pierre Bonnette; Françoise Le Pimpec Barthes; Edouard Paris; Christian Perigaud; Alexia Savignoni; Marc-André Mahé
Journal:  Radiother Oncol       Date:  2011-08-22       Impact factor: 6.280

4.  Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma.

Authors:  Marc de Perrot; Ronald Feld; Natasha B Leighl; Andrew Hope; Thomas K Waddell; Shaf Keshavjee; B C John Cho
Journal:  J Thorac Cardiovasc Surg       Date:  2015-10-19       Impact factor: 5.209

5.  Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma.

Authors:  Claus Andrup Kristensen; Trine Juhler Nøttrup; Anne Kiil Berthelsen; Flemming Kjaer-Kristoffersen; Jesper Ravn; Jens Benn Sørensen; Svend-Aage Engelholm
Journal:  Radiother Oncol       Date:  2009-04-11       Impact factor: 6.280

6.  Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.

Authors:  Rolf A Stahel; Oliver Riesterer; Alexandros Xyrafas; Isabelle Opitz; Michael Beyeler; Adrian Ochsenbein; Martin Früh; Richard Cathomas; Kristiaan Nackaerts; Solange Peters; Christoph Mamot; Alfred Zippelius; Carlo Mordasini; Clemens B Caspar; Katrin Eckhardt; Ralph A Schmid; Daniel M Aebersold; Oliver Gautschi; Wolfgang Nagel; Michael Töpfer; Jerome Krayenbuehl; Karin Ribi; Ilja Ciernik; Walter Weder
Journal:  Lancet Oncol       Date:  2015-11-02       Impact factor: 41.316

7.  Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.

Authors:  Raja M Flores; Harvey I Pass; Venkatraman E Seshan; Joseph Dycoco; Maureen Zakowski; Michele Carbone; Manjit S Bains; Valerie W Rusch
Journal:  J Thorac Cardiovasc Surg       Date:  2008-02-14       Impact factor: 5.209

8.  Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience.

Authors:  Edward F Miles; Nicole A Larrier; Christopher R Kelsey; Jessica L Hubbs; Jinli Ma; Sua Yoo; Lawrence B Marks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-02-08       Impact factor: 7.038

9.  Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.

Authors:  Raffit Hassan; Elad Sharon; Anish Thomas; Jingli Zhang; Alexander Ling; Markku Miettinen; Robert J Kreitman; Seth M Steinberg; Kevin Hollevoet; Ira Pastan
Journal:  Cancer       Date:  2014-07-02       Impact factor: 6.921

10.  Geometric dose prediction model for hemithoracic intensity-modulated radiation therapy in mesothelioma patients with two intact lungs.

Authors:  LiCheng Kuo; Ellen D Yorke; Vishruta A Dumane; Amanda Foster; Zhigang Zhang; James G Mechalakos; Abraham J Wu; Kenneth E Rosenzweig; Andreas Rimner
Journal:  J Appl Clin Med Phys       Date:  2016-05       Impact factor: 2.102
View more
  4 in total

Review 1.  New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma.

Authors:  Marika Rossini; Paola Rizzo; Ilaria Bononi; Anthony Clementz; Roberto Ferrari; Fernanda Martini; Mauro G Tognon
Journal:  Front Oncol       Date:  2018-04-03       Impact factor: 6.244

2.  Surgical staging and resection of malignant pleural mesothelioma.

Authors:  Lawrence B Brown; Frank Corl; Shanda H Blackmon
Journal:  J Thorac Dis       Date:  2020-12       Impact factor: 3.005

3.  Radical Hemithoracic Radiotherapy Induces Systemic Metabolomics Changes That Are Associated with the Clinical Outcome of Malignant Pleural Mesothelioma Patients.

Authors:  Emanuela Di Gregorio; Gianmaria Miolo; Asia Saorin; Elena Muraro; Michela Cangemi; Alberto Revelant; Emilio Minatel; Marco Trovò; Agostino Steffan; Giuseppe Corona
Journal:  Cancers (Basel)       Date:  2021-01-29       Impact factor: 6.639

4.  Biological Pathways Associated With the Development of Pulmonary Toxicities in Mesothelioma Patients Treated With Radical Hemithoracic Radiation Therapy: A Preliminary Study.

Authors:  Sergio Crovella; Alberto Revelant; Elena Muraro; Ronald Rodrigues Moura; Lucas Brandão; Marco Trovò; Agostino Steffan; Paola Zacchi; Giuliano Zabucchi; Emilio Minatel; Violetta Borelli
Journal:  Front Oncol       Date:  2021-12-22       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.